Learn more about diagnostic criteria for Parkinson's disease*
Click here
Download and print
copies of clinical tools
Click here
*  You will need Adobe® Reader®  to download
this file. If you don't have
Adobe Reader, click here
for a free and secure
download.

FOR THE INITIAL AND LONG-TERM TREATMENT OF PARKINSON'S DISEASE (PD)

MIRAPEX offers benefits in
combination with levodopa

Improves functioning in advanced disease2,6,20

MIRAPEX improves "on" time, reduces "off " time, and improves UPDRS ADL* scores2,3,20 Learn more

Improves tremor scores—including levodopa-resistant tremor7

MIRAPEX significantly improves UPDRS tremor and ADL scores7 Learn more

Reserves the use of levodopa6,21

MIRAPEX helps to reserve the dose of levodopa6,21 Learn more

Learn how combination therapy with MIRAPEX improves patient functioning

*UPDRS=Unified Parkinson's Disease Rating Scale; ADL=activities of daily living.

 
 

Important Information about MIRAPEX: MIRAPEX is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease (PD).

Patients have reported falling asleep without perceived warning signs during activities of daily living, including operation of a motor vehicle, which sometimes resulted in accidents. Hallucinations and postural (orthostatic) hypotension may occur. In clinical trials for early PD, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are nausea (28% vs. 18%), dizziness (25% vs. 24%), somnolence (22% vs. 9%), insomnia (17% vs. 12%), asthenia (14% vs. 12%), and constipation (14% vs. 6%). In clinical trials for advanced PD, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are postural hypotension (53% vs. 48%), dyskinesia (47% vs. 31%), extrapyramidal syndrome (28% vs. 26%), insomnia (27% vs. 22%), dizziness (26% vs. 25%), accidental injury (17% vs. 15%), hallucinations (17% vs. 4%), and dream abnormalities (11% vs. 10%).

Patients and caregivers should be informed that impulse control disorders and compulsive behaviors have been reported in patients taking dopamine agonists, including MIRAPEX.

Please see full Prescribing Information.

This information is intended for U.S. residents only.